Skip to main content

Advertisement

SpringerLink
Log in

Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

Using a computer simulation model, we determined that an intervention aimed at improving the management of glucocorticoid-induced osteoporosis is likely to be cost-effective to third-party health insurers only if it focuses on individuals with very high fracture risk and the proportion of prescriptions for generic bisphosphonates increases substantially.

Introduction

The purpose of this study is to determine whether an evidence implementation program (intervention) focused on increasing appropriate management of glucocorticoid-induced osteoporosis (GIOP) might be cost-effective compared with current practice (no intervention) from the perspective of a third-party health insurer.

Methods

We developed a Markov microsimulation model to determine the cost-effectiveness of the intervention. The hypothetical patient cohort was of current chronic glucocorticoid users 50–65 years old and 70% female. Model parameters were derived from published literature, and sensitivity analyses were performed.

Results

The intervention resulted in incremental cost-effectiveness ratios (ICERs) of $298,000 per quality adjusted life year (QALY) and $206,000 per hip fracture averted. If the cohort's baseline risk of fracture was increased by 50% (10-year cumulative incidence of hip fracture of 14%), the ICERs improved significantly: $105,000 per QALY and $137,000 per hip fracture averted. The ICERs improved significantly if the proportion of prescriptions for generic bisphosphonates was increased to 75%, with $113,000 per QALY and $77,900 per hip fracture averted.

Conclusions

Evidence implementation programs for the management of GIOP are likely to be cost-effective to third-party health insurers only if they are targeted at individuals with a very high risk of fracture and the proportion of prescriptions for less expensive generic bisphosphonates increases substantially.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C (2000) Use of oral corticosteroids in the United Kingdom. QJM 93(2):105–111

    Article  PubMed  Google Scholar 

  2. Walsh LJ, Wong CA, Pringle M, Tattersfield AE (1996) Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313(7053):344–346

    CAS  PubMed  Google Scholar 

  3. Mudano A, Allison J, Hill J, Rothermel T, Saag K (2001) Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol 28(6):1298–1305

    CAS  PubMed  Google Scholar 

  4. Curtis JR, Westfall AO, Allison J, Becker A, Melton ME, Freeman A et al (2007) Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial. Arch Intern Med 167(6):591–596

    Article  PubMed  Google Scholar 

  5. Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11(7):iii-iv, ix-xi, 1–231

    Google Scholar 

  6. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol (Oxford) 39(12):1383–1389

    Article  Google Scholar 

  7. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15(6):993–1000

    Article  PubMed  Google Scholar 

  8. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001;44(7):1496–1503

    Google Scholar 

  9. Adler RA, Hochberg MC (2003) Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the department of veterans affairs. Arch Intern Med 163(21):2619–2624

    Article  PubMed  Google Scholar 

  10. Geusens PP, de Nijs RN, Lems WF, Laan RF, Struijs A, van Staa TP et al (2004) Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch society for rheumatology. Ann Rheum Dis 63(3):324–325

    Article  CAS  PubMed  Google Scholar 

  11. Curtis JR, Westfall AO, Allison JJ, Becker A, Casebeer L, Freeman A et al (2005) Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 52(8):2485–2494

    Article  PubMed  Google Scholar 

  12. Institute of Medicine (2001) Crossing the quality chasm: a new health system for the 21st century. National Academy Press, Washington D.C

    Google Scholar 

  13. Naunton M, Peterson GM, Jones G, Griffin GM, Bleasel MD (2004) Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol 31(3):550–556

    PubMed  Google Scholar 

  14. Solomon DH, Katz JN, La Tourette AM, Coblyn JS (2004) Multifaceted intervention to improve rheumatologists' management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum 51(3):383–387

    Article  CAS  PubMed  Google Scholar 

  15. Weinstein MC (2006) Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 24(11):1043–1053

    Article  PubMed  Google Scholar 

  16. Solomon DH, Kuntz KM (2000) Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis. Arthritis Rheum 43(9):1967–1975

    Article  CAS  PubMed  Google Scholar 

  17. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E (2008) Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 23(9):1435–1441

    Article  PubMed  Google Scholar 

  18. Hooven F, Gehlbach SH, Pekow P, Bertone E, Benjamin E (2005) Follow-up treatment for osteoporosis after fracture. Osteoporos Int 16(3):296–301

    Article  PubMed  Google Scholar 

  19. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24):2927–2938

    Article  CAS  PubMed  Google Scholar 

  20. Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19(11):1613–1620

    Article  CAS  PubMed  Google Scholar 

  21. Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES et al (2007) Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 298(6):629–637

    Article  CAS  PubMed  Google Scholar 

  22. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013–1022

    Article  PubMed  Google Scholar 

  23. Singer BR, McLauchlan GJ, Robinson CM, Christie J (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80(2):243–248

    Article  CAS  PubMed  Google Scholar 

  24. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton IL et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19(6):893–899

    Article  PubMed  Google Scholar 

  25. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54(10):3104–3112

    Article  PubMed  Google Scholar 

  26. van Staa TP, Geusens P, Pols HA, de Laet C, Leufkens HG, Cooper C (2005) A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 98(3):191–198

    Article  PubMed  Google Scholar 

  27. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A et al (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11(8):669–674

    Article  CAS  PubMed  Google Scholar 

  28. Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model. Osteoporos Int 18(1):9–23

    Article  CAS  PubMed  Google Scholar 

  29. Tosteson AN, Gottlieb DJ, Radley DC, Fisher ES, Melton LJ 3rd (2007) Excess mortality following hip fracture: the role of underlying health status. Osteoporos Int 18(11):1463–1472

    Article  CAS  PubMed  Google Scholar 

  30. Forsen L, Sogaard AJ, Meyer HE, Edna T, Kopjar B (1999) Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 10(1):73–78

    Article  CAS  PubMed  Google Scholar 

  31. Meyer HE, Tverdal A, Falch JA, Pedersen JI (2000) Factors associated with mortality after hip fracture. Osteoporos Int 11(3):228–232

    Article  CAS  PubMed  Google Scholar 

  32. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15(1):38–42

    Article  CAS  PubMed  Google Scholar 

  33. Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P et al (2003) Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18(7):1254–1260

    Article  PubMed  Google Scholar 

  34. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11(7):556–561

    Article  CAS  PubMed  Google Scholar 

  35. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156):878–882

    Article  CAS  PubMed  Google Scholar 

  36. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137(9):1001–1005

    CAS  PubMed  Google Scholar 

  37. Red Book (2007) Pharmacy's fundamental reference (Drug Topics Red Book). Thomson Healthcare Inc, Montvale, NJ

    Google Scholar 

  38. Kilgore ML, Morrisey MA, Becker DJ, Gary LC, Curtis JR, Saag KG et al (2009) Health care expenditures associated with skeletal fractures among Medicare beneficiaries, 1999-2005. J Bone Miner Res. doi:10.1359/jbmr.090523

  39. Uhlig T, Loge JH, Kristiansen IS, Kvien TK (2007) Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol 34(6):1241–1247

    PubMed  Google Scholar 

  40. Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21(5):305–314

    Article  PubMed  Google Scholar 

  41. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C et al (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15(1):20–26

    Article  CAS  PubMed  Google Scholar 

  42. Merlino LA, Bagchi I, Taylor TN, Utrie P, Chrischilles E, Sumner W 2nd et al (2001) Preference for fractures and other glucocorticoid-associated adverse effects among rheumatoid arthritis patients. Med Decis Making 21(2):122–132

    CAS  PubMed  Google Scholar 

  43. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721–739

    Article  CAS  PubMed  Google Scholar 

  44. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35(2):375–382

    Article  CAS  PubMed  Google Scholar 

  45. Arias E (2006) United States life tables, 2003. National vital statistics reports; vol 54 no 14. National Center for Health Statistics, Hyattsville, MD

    Google Scholar 

  46. Kilgore ML, Gary LC, Curtis JR, Saag KG, Arora T, Morrisey MA et al (2008) Incremental costs associated with selected skeletal fractures among Medicare beneficiaries [abstract]. Annual Meeting of the American Society for Bone and Mineral Research

  47. Gold MR, Patrick DL, Torrance GW, Fryback DG, Hadorn DC, Kamlet MS et al (1996) Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russell LB, Weinstein MC (eds) Cost-effectiveness in health and medicine. Oxford University Press, New York, pp 82–123

    Google Scholar 

  48. Claxton K (2008) Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics 26(9):781–798

    Article  PubMed  Google Scholar 

  49. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH (2000) Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 19(2):92–109

    Article  CAS  Google Scholar 

  50. World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAX: WHO fracture risk assessment tool. University of Sheffield, UK (http://www.shef.ac.uk/FRAX/index.htm)

  51. Express Scripts 2007 Drug Trend Report.Available from:http://www.express-scripts.com/industryresearch/industryreports/drugtrendreport/2007/trend.pdf

  52. Landon BE, Rosenthal MB, Normand SL, Frank RG, Epstein AM (2008) Quality monitoring and management in commercial health plans. Am J Manag Care 14(6):377–386

    PubMed  Google Scholar 

  53. Newman ED, Matzko CK, Olenginski TP, Perruquet JL, Harrington TM, Maloney-Saxon G et al (2006) Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int 17(9):1428–1434

    Article  CAS  PubMed  Google Scholar 

  54. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48(11):3224–3229

    Article  PubMed  Google Scholar 

  55. Cockerill W, Lunt M, Silman AJ, Cooper C, Lips P, Bhalla AK et al (2004) Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 15(2):113–119

    Article  CAS  PubMed  Google Scholar 

  56. Harrison RA, Siminoski K, Vethanayagam D, Majumdar SR (2007) Osteoporosis-related kyphosis and impairments in pulmonary function: a systematic review. J Bone Miner Res 22(3):447–457

    Article  PubMed  Google Scholar 

  57. Lu CY, Ross-Degnan D, Soumerai SB, Pearson SA (2008) Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature—2001–2007. BMC Health Serv Res 8:75

    Article  PubMed  Google Scholar 

  58. Majumdar SR, Johnson JA, Lier DA, Russell AS, Hanley DA, Blitz S et al (2007) Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial. Osteoporos Int 18(3):261–270

    Article  CAS  PubMed  Google Scholar 

  59. Buckley LM, Hillner BE (2003) A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. J Rheumatol 30(1):132–138

    CAS  PubMed  Google Scholar 

  60. van Staa TP, Geusens P, Zhang B, Leufkens HG, Boonen A, Cooper C (2007) Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. Rheumatol (Oxford) 46(3):460–466

    Article  Google Scholar 

Download references

Acknowledgement

We thank Drs. Anna Tosteson and Rick Adachi for critical evaluation of the decision model structure and parameters and Dr. Raj Nair for assistance with the literature search.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. University of Alabama at Birmingham Deep South Musculoskeletal Center for Education and Research on Therapeutics, Birmingham, AL, USA

    T. Beukelman, K. G. Saag, J. R. Curtis, M. L. Kilgore & M. Pisu

  2. The University of Alabama at Birmingham, 1530 3rd Avenue South MT 628, Birmingham, AL, 35294-4410, USA

    M. Pisu

  3. The University of Alabama at Birmingham, 1530 3rd Avenue South FOT 838, Birmingham, AL, 35294-3408, USA

    T. Beukelman

Authors
  1. T. Beukelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. G. Saag
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. R. Curtis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. L. Kilgore
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Pisu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Beukelman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beukelman, T., Saag, K.G., Curtis, J.R. et al. Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. Osteoporos Int 21, 1573–1584 (2010). https://doi.org/10.1007/s00198-009-1114-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-009-1114-8

Keywords

Search

Navigation